title: [Our experince with the use of recombinant activated factor VII in postpartum haemorrhage].
abstract: BACKGROUND
  Massive obstetric bleeding is the most common cause of maternal mortality and morbidity. The first step in treatment of these patients is establishing the adequate circulatory volume. The primary goal of therapy is to identify and remove the cause of bleeding, with appropriate symptomatic and substitution therapy. Human recombinant activated factor VII (rFVIIa) is officially registered for the treatment of patients suffering from haemophilia with inhibitors. Its use has also proved successful in other congenital and acquired coagulopathies and in patients with acute non-haemophilic bleeding. A special significance is given to the application of rFVIIa in cases of obstetric haemorrhage, in order to avoid postpartum hysterectomy and occurrence of complications of haemorrhagic shock in obstetrics.
  
  
  OBJECTIVE
  The aim of this study is to show our experience and results of the use of rFVIIa in the treatment of patients with massive postpartum bleeding.
  
  
  METHODS
  The retrospective study encompassed six patients with primary postpartum haemorrhage treated with rFVIIa at our institution in the period from 2005 to 2007.
  
  
  RESULTS
  The treated patients were divided into two groups. In the first group, there were three patients who underwent hysterectomy and who received rFVIIa over 24 hours after delivery. The second group consisted of three patients who received rFVIIa in the first 24 hours after delivery, before we decided to perform hysterectomy. The application of rFVIIa led to successful cessation of bleeding in all patients. Relevant side effects were not registered.
  
  
  CONCLUSIONS
  The administration of rFVIIa in obstetrics should be considered for each patient before decision to apply hysterectomy, and it should certainly be applied in patients who want to preserve the uterus and fertile capability. According to our experience, in cases of postpartum hemorrhagia rFVIIa is to be administered in intravenous bolus doses of at least 90 mcg/kg, at least 6 hours after the onset of bleeding. rFVIIa is not an alternative to adequate surgical haemostasis; therefore, it needs to be administered after its detailed revision.
authors: Tatjana
authors: T
authors: Mostić
authors: Radmila
authors: R
authors: Sparić
authors: Rajka
authors: R
authors: Argirović
authors: Aleksandar
authors: A
authors: Ljubić
authors: Tatjana
authors: T
authors: Bozanović
authors: Ljubica
authors: L
authors: Arsenijević
authors: Jelena
authors: J
authors: Tomanović-Koković
authors: Aleksandar
authors: A
authors: Stefanović
mesh_terms: D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D007044:Hysterectomy; D006473:Postpartum Hemorrhage / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D011247:Pregnancy; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D006490:Hemostatics; D011994:Recombinant Proteins; C103587:recombinant FVIIa; D015942:Factor VIIa